Literature DB >> 32999121

Rescue Treatment with Terlipressin for Persistent Pulmonary Hypertension and Refractory Shock in a Preterm Infant.

Ignacio Oulego-Erroz1, Sandra Terroba-Seara2, Leticia Castanon-Lopez3, Antonio Rodriguez-Nunez4.   

Abstract

Entities:  

Year:  2020        PMID： 32999121      PMCID： PMC7498553     

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN： 0019-6061            Impact factor:   1.411


× No keyword cloud information.
  6 in total

Review 1.  Persistent pulmonary hypertension of the newborn.

Authors:  Mamta Fuloria; Judy L Aschner
Journal:  Semin Fetal Neonatal Med       Date:  2017-03-23       Impact factor: 3.926

2.  Terlipressin as rescue therapy for refractory pulmonary hypertension in a neonate with a congenital diaphragmatic hernia.

Authors:  Lefteris Stathopoulos; Claire Nicaise; Fabrice Michel; Laurent Thomachot; Thierry Merrot; Pierre Lagier; Claude Martin
Journal:  J Pediatr Surg       Date:  2011-02       Impact factor: 2.545

3.  Effects of terlipressin on pulmonary artery pressure in a septic cooled infant: an echocardiographic assessment.

Authors:  M Radicioni; S Troiani; P G Camerini
Journal:  J Perinatol       Date:  2012-11       Impact factor: 2.521

4.  Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide.

Authors:  P R Evora; P J Pearson; H V Schaff
Journal:  Chest       Date:  1993-04       Impact factor: 9.410

Review 5.  Role of vasopressin and terlipressin in refractory shock compared to conventional therapy in the neonatal and pediatric population: a systematic review, meta-analysis, and trial sequential analysis.

Authors:  Reem Masarwa; Gideon Paret; Amichai Perlman; Shimon Reif; Bruria Hirsh Raccah; Ilan Matok
Journal:  Crit Care       Date:  2017-01-05       Impact factor: 9.097

6.  Rescue treatment with terlipressin in children with refractory septic shock: a clinical study.

Authors:  Antonio Rodríguez-Núñez; Jesús López-Herce; Javier Gil-Antón; Arturo Hernández; Corsino Rey
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.